Patents Assigned to J. Craig Venter Institute, Inc.
  • Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
    Patent number: 11964944
    Abstract: Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: April 23, 2024
    Assignees: The University of Chicago, J. Craig Venter Institute, Inc., The University of Sheffield, Institute for Systems Biology, The University of Leeds, The University of Strathclyde, The Government of the United States
    Inventors: Rima McLeod, Martin McPhillie, Colin W. G. Fishwick, Hernan Alejandro Lorenzi, Kai Wang, Taek-Kyun Kim, Yong Zhou, Leroy E. Hood, Ying Zhou, Kamal El Bissati, Mark Hickman, QiGui Li, Craig Roberts
  • Nucleic acids and proteins from streptococcus groups A and B
    Patent number: 10428121
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 1, 2019
    Assignees: Novartis AG, J. Craig Venter Institute, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI
    Publication number: 20180298064
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 18, 2018
    Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.
    Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Hervé TETTELIN
  • Nucleic acids and proteins from groups A and B
    Patent number: 9840538
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: December 12, 2017
    Assignees: Novartis AG, J. Craig Venter Institute, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • bacteriophage and uses thereof
    Patent number: 9795642
    Abstract: Bacteriophages are provided that infect strains of Enterococcus faecalis, an opportunistic bacterial pathogen that causes human disease. Also provided are methods of treating Enterococcus faecalis by therapeutic administration of such bacteriophages.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: October 24, 2017
    Assignees: TEMPLE UNIVERSITY—Of The Commonwealth System of Higher Education, J. Craig Venter Institute, Inc.
    Inventors: Roy H. Stevens, Hongming Zhang, Derrick E. Fouts, Jessica DePew
  • Nucleic acids and proteins from streptococcus groups A and B
    Patent number: 9738693
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 22, 2017
    Assignees: Novartis AG, J. Craig Venter Institute, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI
    Publication number: 20160244489
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
    Type: Application
    Filed: May 9, 2016
    Publication date: August 25, 2016
    Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.
    Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
  • HAEMOPHILUS INFLUENZAE TYPE B
    Publication number: 20160024157
    Abstract: Polypeptides comprising various amino acid sequences derived from Haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis. They may also be useful for diagnostic purposes, and as targets for antibiotics. Antibodies against the polypeptides are also disclosed, as are the coding nucleic acids.
    Type: Application
    Filed: October 6, 2015
    Publication date: January 28, 2016
    Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, J. CRAIG VENTER INSTITUTE, INC.
    Inventors: Vega MASIGNANI, Rino RAPPUOLI, Herve TETTELIN
  • PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI
    Publication number: 20140356389
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
    Type: Application
    Filed: June 2, 2014
    Publication date: December 4, 2014
    Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS SRL
    Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
  • antigens and compositions
    Patent number: 8524251
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: September 3, 2013
    Assignees: J. Craig Venter Institute, Inc., Novartis AG
    Inventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
  • Polypeptides from
    Patent number: 8491918
    Abstract: Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: July 23, 2013
    Assignees: J. Craig Venter Institute, Inc., Novartis AG
    Inventors: Rino Rappuoli, Claire Fraser, Mariagrazia Pizza, Maria Scarselli, Davide Serruto, Hervé Tettelin
  • NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B
    Publication number: 20120207778
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences.
    Type: Application
    Filed: February 16, 2012
    Publication date: August 16, 2012
    Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Inventors: John Telford, Vega Masignani, Immaculada Margarit Y Ros, Guido Grandi, Claire Fraser, Hervé Tettelin
  • NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS
    Publication number: 20120164166
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Application
    Filed: January 26, 2012
    Publication date: June 28, 2012
    Applicants: NOVARTIS AG, J. CRAIG VENTER INSTITUTE, INC.
    Inventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
  • NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS
    Publication number: 20120156236
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Application
    Filed: January 26, 2012
    Publication date: June 21, 2012
    Applicants: NOVARTIS AG, J. CRAIG VENTER INSTITUTE, INC.
    Inventors: Claire FRASER, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
  • NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS
    Publication number: 20120148616
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Application
    Filed: January 26, 2012
    Publication date: June 14, 2012
    Applicants: NOVARTIS AG, J. CRAIG VENTER INSTITUTE, INC.
    Inventors: Claire FRASER, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
  • NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS
    Publication number: 20120135024
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Application
    Filed: March 23, 2011
    Publication date: May 31, 2012
    Applicants: NOVARTIS AG, J. CRAIG VENTER INSTITUTE, INC.
    Inventors: Claire FRASER, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
  • HAEMOPHILUS INFLUENZAE TYPE B
    Publication number: 20120093868
    Abstract: Polypeptides comprising various amino acid sequences derived from Haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis. They may also be useful for diagnostic purposes, and as targets for antibiotics. Antibodies against the polypeptides are also disclosed, as are the coding nucleic acids.
    Type: Application
    Filed: December 21, 2011
    Publication date: April 19, 2012
    Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS SRL
    Inventors: Vega MASIGNANI, Rino Rappuoli, Herve Tettelin
  • Polypeptides from neisseria meningitidis
    Publication number: 20120070457
    Abstract: Polypeptides comprising Neisseria meningitidis amino acid sequences. Over 36000 meningococcal polypeptide sequences are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be usedin medicine for treating or preventing disease and/or infection caused by N. meningitidis, such as meningococcal meningitis.
    Type: Application
    Filed: September 8, 2011
    Publication date: March 22, 2012
    Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS AG
    Inventors: Sean C. Daugherty, Julie C. Dunning Hotopp, David R. Riley, Samuel V. Angiuoli, Heather Huot Creasy, Todd H. Creasy, Herve Tettelin, Duccio Medini, Emilio Siena, Sonia Budroni, Maria Scarselli
  • POLYPEPTIDES FROM NEISSERIA MENINGITIDIS
    Publication number: 20120027801
    Abstract: Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis.
    Type: Application
    Filed: October 13, 2011
    Publication date: February 2, 2012
    Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS AG
    Inventors: Rino Rappuoli, Claire Fraser, Mariagrazia Pizza, Maria Scarselli, Davide Serruto, Hervé Tettelin
  • Polypeptides from
    Patent number: 8039007
    Abstract: Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: October 18, 2011
    Assignees: J. Craig Venter Institute, Inc., Novartis AG
    Inventors: Rino Rappuoli, Claire Fraser, Mariagrazia Pizza, Maria Scarselli, Davide Serruto, Hervé Tettelin